Middle East respiratory syndrome–related coronavirus

Middle East respiratory syndrome–related coronavirus
Name	Middle East respiratory syndrome–related coronavirus
Virus group	Group 2c betacoronavirus
Species	Severe acute respiratory syndrome–related coronavirus
Genus	Betacoronavirus
Family	Coronaviridae
Subfamily	Orthocoronavirinae
Genome	Positive-sense single-stranded RNA
Capsid	Enveloped, helical
Hosts	Humans, dromedary camels
Diseases	Middle East respiratory syndrome
First isolation	2012
Location	Middle East

Middle East respiratory syndrome–related coronavirus is a zoonotic betacoronavirus first recognized in 2012 that causes Middle East respiratory syndrome (MERS) in humans. Identified through international laboratory collaboration, the virus links human respiratory disease to dromedary camels and to molecular lineages related to coronaviruses detected in bats. Public health responses have involved agencies and institutions across the Middle East, Europe, Asia, and North America.

Virology

The virus belongs to the genus Betacoronavirus within the family Coronaviridae, sharing genomic and structural features with Severe acute respiratory syndrome coronavirus 2 and Severe acute respiratory syndrome coronavirus. Its positive-sense single-stranded RNA genome encodes replicase proteins, structural proteins including spike (S), envelope (E), membrane (M), and nucleocapsid (N), and accessory proteins implicated in host interaction; genome organization and open reading frames were described by teams at the World Health Organization, Centers for Disease Control and Prevention, and major virology research centers such as the Pasteur Institute and the University of Hong Kong. The spike glycoprotein mediates attachment via the dipeptidyl peptidase 4 receptor characterized in structural studies involving groups from Columbia University, Harvard Medical School, and the National Institutes of Health. Phylogenetic analyses published by consortia including researchers from the Wellcome Trust and the Scripps Research Institute place the virus in a clade related to coronaviruses sampled from bats in China, Saudi Arabia, and Kenya.

Epidemiology

Epidemiologic patterns were documented through surveillance networks coordinated by the World Health Organization, national ministries of health such as those of Saudi Arabia, United Arab Emirates, and South Korea, and international laboratories including the European Centre for Disease Prevention and Control and the Robert Koch Institute. Cases have been concentrated in the Arabian Peninsula with exportation linked to travel and pilgrimage to Mecca and Medina; notable nosocomial amplifications occurred in hospitals studied by investigators from Seoul National University and the London School of Hygiene & Tropical Medicine. Serologic surveys in pastoral regions and camel herds were carried out by teams from the International Livestock Research Institute and the Food and Agriculture Organization, documenting widespread seropositivity in dromedary camels across Egypt, Oman, and Sudan. Case fatality ratios estimated early in outbreaks were reported by groups at Johns Hopkins University and the Imperial College London and influenced travel advisories issued by the European Union and the United States Department of State.

Transmission and Pathogenesis

Zoonotic spillover is attributed to direct and indirect camel contact established by field investigations involving specialists from the Ministry of Health (Saudi Arabia), the Royal Veterinary College, and the University of Cambridge. Human-to-human transmission occurs primarily via respiratory droplets and close contact; hospital-associated spread was characterized in outbreak reports involving the Samsung Medical Center, King Abdulaziz University Hospital, and other referral centers. Viral entry via DPP4 expressed on respiratory epithelium, and subsequent replication in lower airway tissues, was elucidated by structural biologists at institutions such as the Max Planck Institute and the California Institute of Technology. Pathogenesis studies in animal models developed at the University of North Carolina at Chapel Hill and the Rocky Mountain Laboratories demonstrated severe pneumonia, immune dysregulation, and extrapulmonary involvement that informed clinical management guidelines by the World Health Organization.

Clinical Presentation and Diagnosis

Clinical descriptions from cohorts treated at King Fahd Hospital of the University, Asan Medical Center, and Mayo Clinic document presentations ranging from asymptomatic infection to severe acute respiratory failure with acute kidney injury. Common symptoms include fever, cough, dyspnea, and gastrointestinal complaints; laboratory and radiologic features have been reported by multidisciplinary teams at Cleveland Clinic and Mount Sinai Health System. Diagnostic confirmation relies on real-time reverse-transcription PCR assays developed by the Centers for Disease Control and Prevention, validated by reference laboratories such as those at the Public Health England and the National Institute for Viral Disease Control and Prevention (China), and on serologic assays used in epidemiologic studies.

Treatment and Prevention

There is no pathogen-specific antiviral therapy conclusively proven in randomized trials; investigational treatments evaluated in clinical and preclinical studies involved repurposed antivirals and immunotherapies tested at centers including Université de Montréal, Mayo Clinic, and the National Institutes of Health Clinical Center. Supportive care in intensive care units at tertiary hospitals such as Asan Medical Center and St Thomas' Hospital remains central. Prevention strategies include infection control in healthcare settings promulgated by World Health Organization guidance, occupational measures for camel handlers promoted by the Food and Agriculture Organization, and travel-health advisories issued by the Centers for Disease Control and Prevention and national health ministries.

History and Outbreaks

The pathogen was first linked to human disease in 2012 following cluster investigations reported by clinicians at Sultanahmet Hospital and researchers affiliated with the King Abdulaziz Medical City and the University of Bonn. Major outbreaks include the 2015 South Korea epidemic seeded by a traveler and amplified in hospitals studied by the Korean Centers for Disease Control and Prevention, and recurrent sporadic cases and hospital clusters in the Arabian Peninsula documented by the World Health Organization and national surveillance systems. International research collaborations, including consortia funded by the Wellcome Trust and the Bill & Melinda Gates Foundation, supported genomic sequencing and public health studies that traced zoonotic links and transmission chains.

Research and Vaccine Development

Vaccine candidates and immunotherapeutics have been developed by academic and industry teams at Moderna, Inc., Inovio Pharmaceuticals, University of Oxford, and the National Institutes of Health, with preclinical efficacy assessed in models at the Rocky Mountain Laboratories and translational studies coordinated with the Coalition for Epidemic Preparedness Innovations. Structural vaccinology informed by groups at the Scripps Research Institute and Ragon Institute targeted the spike protein; monoclonal antibodies were advanced by collaborations involving Regeneron Pharmaceuticals and academic partners. Ongoing surveillance, basic science at institutions like the Pasteur Institute and Harvard Medical School, and coordinated public health efforts by the World Health Organization continue to shape preparedness for future zoonotic coronaviruses.

Category:Coronaviruses